Targeting a specific signaling pathway to treat advanced prostate cancer with SPOP mutations
Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate Cancer
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-10931370
This study is looking at how changes in the SPOP gene might help prostate cancer grow and resist treatment, and it’s inviting patients to join in clinical trials to explore new ways to fight this tough form of cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10931370 on ClinicalTrials.gov |
What this research studies
This research investigates how mutations in the SPOP gene contribute to the development of castration-resistant prostate cancer (CRPC). By focusing on the non-canonical STING signaling pathway, the study aims to understand the role of these mutations in tumor growth and survival. The researchers will analyze clinical data and utilize advanced cancer models to explore the effects of these mutations on tumor behavior and response to treatments. Patients may have the opportunity to contribute to this research through participation in clinical trials that evaluate new therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for participation are patients diagnosed with castration-resistant prostate cancer who have SPOP mutations.
Not a fit: Patients with prostate cancer who do not have SPOP mutations may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with SPOP mutant castration-resistant prostate cancer.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: THOMPSON, TIMOTHY CHARLES — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: THOMPSON, TIMOTHY CHARLES
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.